IBIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
IBIO, INC. (IBIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $23.96 per share for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2023-09-27
- IBIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2018-09-30 was $4.00.
- IBIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $23.96, a 31.54% decline from fiscal 2022.
- IBIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $35.00, a 42.86% decline from fiscal 2021.
- IBIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $61.25, a 1744.88% increase from fiscal 2020.
- IBIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2020 was $3.32, a 72.52% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 24 month |
|---|---|---|---|---|---|---|
| 2023-06-30 | $23.96 10-K · filed 2023-09-27 | |||||
| 2022-06-30 | $35.00 10-K · filed 2023-09-27 | |||||
| 2021-06-30 | $61.25 10-K · filed 2022-10-11 | $2.45 10-K · filed 2021-09-28 | ||||
| 2020-06-30 | $3.32 10-K · filed 2021-09-28 | |||||
| 2020-03-31 | $3.80 10-Q · filed 2020-05-15 | |||||
| 2019-12-31 | $3.95 10-Q · filed 2020-02-14 | |||||
| 2019-06-30 | $12.08 10-K · filed 2019-08-26 | $12.08 10-K · filed 2020-10-13 | ||||
| 2019-03-31 | $12.08 10-Q · filed 2019-05-10 | |||||
| 2018-12-31 | $10.51 10-Q · filed 2019-02-13 | |||||
| 2018-09-30 | $4.00 10-Q · filed 2018-11-13 | |||||
| 2018-06-30 | $4.00 10-K · filed 2019-08-26 | |||||
| 2018-03-31 | $0.40 10-Q · filed 2018-05-11 | |||||
| 2017-12-31 | $0.40 10-Q · filed 2018-02-14 | |||||
| 2017-06-30 | $11.11 10-K · filed 2018-09-18 | $1.11 10-K · filed 2017-09-15 | ||||
| 2017-03-31 | $1.54 10-Q · filed 2017-05-15 | |||||
| 2016-06-30 | $0.00 10-K · filed 2017-09-15 | |||||
| 2015-06-30 | $0.75 10-K · filed 2016-10-13 | |||||
| 2015-03-31 | $0.87 10-Q · filed 2015-05-15 | |||||
| 2014-12-31 | $0.87 10-Q · filed 2015-02-24 | |||||
| 2014-06-30 | $0.62 10-K · filed 2015-10-13 | |||||
| 2013-06-30 | $1.55 10-K · filed 2014-09-29 | |||||
| 2012-12-31 | $1.55 10-Q · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |